Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Calyxt, Inc. (Nasdaq: CLXT) has successfully completed a 1-for-10 reverse stock split of its common stock, effective April 24, 2023. This decision was approved by shareholders on June 1, 2022, and aims to enhance the company's stock price and maintain compliance with Nasdaq listing standards. Post-split, the number of outstanding shares has decreased from approximately 49.7 million to about 5 million, but the total authorized shares remain unchanged. The stock will resume trading on an adjusted basis on April 25, 2023, under the symbol CLXT and a new CUSIP number. The company’s equity-based awards will be adjusted proportionately. No action is required from registered stockholders as their holdings will be automatically updated.
Cellectis has announced the implementation of alemtuzumab as an Investigational Medicinal Product (IMP), coded CLLS52, in its clinical trials for UCART22, UCART123, and UCART20x22. This addition to the lymphodepletion regimen has shown prolonged lymphodepletion and increased cell expansion leading to greater clinical activity. The trials focus on patients with relapsed/refractory B-cell ALL, AML, and NHL. This collaboration with Sanofi, which began in May 2021, involves the supply of alemtuzumab for these studies. The findings from the BALLI-01 and AMELI-01 studies are promising, indicating a significant step forward for Cellectis' allogeneic CAR T-cell therapies, enhancing their therapeutic potential against various cancers.
Cellectis, a clinical-stage biotechnology company specializing in gene-editing, recently presented preclinical data on TALEN®-edited MUC1 CAR T-cells at the AACR Annual Meeting 2023. This research highlights the potential of these CAR T-cells to effectively target relapsed and refractory triple-negative breast cancer (TNBC), a condition with limited treatment options. MUC1, a tumor-associated antigen overexpressed in many TNBC patients, serves as a precise target for the therapy. The preclinical results indicate that the armored MUC1 CAR T-cells could not only control tumor growth but also aid in the recovery of normal tissues. Cellectis aims to leverage the unique properties of MUC1 for innovative and safe CAR T-cell therapies.